Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ProStrakan Group plc

http://www.prostrakan.com/

Latest From ProStrakan Group plc

China Turns To New Vaccines As It Eases 'COVID Zero' Restrictions

In a significant policy shift and following recent public unrest, China now appears to be moving away from its strict "COVID Zero" restrictions to salvage a floundering economy hard hit by repeated lockdowns, as part of which it is looking to accelerate the approval of new vaccines and increase vaccination rates in the elderly.

China Coronavirus COVID-19

Asia Deal Watch: Astellas Invests In Taysha, Gets Rights To Two AAV Gene Therapies

Plus deals involving Takeda/Zedira/Dr. Falk, Lupin/Sunovion, Eucure/Syncromune, Hetero/Johnson & Johnson, Nitto Denko/Omega, Harbour BioMed/CSPC and Pregene/Bone Therapeutics.

Deal Watch Business Strategies

Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode

Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of generic Asacol revenues even as Zydus expects volume growth and new launches to help grow its US business.

Strategy Generic Drugs

Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode

Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of gAsacol revenues even as Zydus expects volume growth and new launches to help grow its US business

Commercial Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Strakan Pharmaceuticals, Ltd.
UsernamePublicRestriction

Register